Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BMS entered an exclusive option to buy Promedior for up to $1.25B, betting on PRM-151's pentraxin-2 anti-fibrotic mechanism as a complement to its expanding…
Roche wagered $1.4B that Promedior had its next big fibrosis drug, validating BMS's original thesis but raising questions about whether BMS's option fee was…
After BMS allowed its option to expire, Roche put up to $1.4B on the table for Promedior, suggesting BMS misjudged either PRM-151's value or its strategic fit…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS acquired an exclusive option to purchase Promedior and worldwide rights to PRM-151 for $150M upfront with up to $1.1B in additional payments tied to the option exercise and clinical/regulatory milestones. BMS allowed the option to expire in 2019 without exercise. Promedior was later acquired by Roche for ~$1.4B in 2020.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Promedior, Inc. (this deal) | 2015 | $1.2B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2015 deals · Bristol-Myers Squibb Company deals · Hematology deals